Skip to main content
Black Health logo Black Health
Policy

CMS's proposed RAPID pathway would cut Medicare device coverage decisions from about a year to as little as two months. Black-Medicare utilization gaps live downstream of the timing change.

Updated 5 min read

Editorial review

Reviewed by the Black Health editorial team against our editorial standards. Last updated . How we source.

A Black physician in a white lab coat reviews records on a tablet in a clinical setting.
Photo: Tima Miroshnichenko / Pexels

The new Centers for Medicare and Medicaid Services Coverage Pathway compresses coverage decisions on FDA Breakthrough Devices from 12-plus months to as little as two. Peer-reviewed evidence on Black-beneficiary access to the devices most likely to flow through RAPID, including AFib catheter ablation, continuous glucose monitors, and automated insulin delivery, shows the utilization gaps persist regardless of how fast coverage...

The new Centers for Medicare and Medicaid Services Coverage Pathway compresses coverage decisions on FDA Breakthrough Devices from 12-plus months to as little as two. Peer-reviewed evidence on Black-beneficiary access to the devices most likely to flow through RAPID, including AFib catheter ablation, continuous glucose monitors, and automated insulin delivery, shows the utilization gaps persist regardless of how fast coverage is determined. Sickle cell disease gene therapy aligns RAPID timing with a Black-majority patient population as the Medicare-aging SCD cohort grows.
On this page

In a 2025 JACC Advances systematic review and meta-analysis of 18 US atrial fibrillation catheter ablation studies, non-Hispanic Black patients were 35 percent less likely to receive catheter ablation than non-Hispanic white patients, after adjusting for relevant clinical factors (Nosair et al., PMID 40857826). The Centers for Medicare and Medicaid Services announced the RAPID Coverage Pathway with the FDA on April 23, 2026, saying it could enable Medicare national coverage for eligible breakthrough devices "as soon as two months after market authorization," compared with "approximately a year or more under the current pathway."

RAPID is coverage-speed reform. The peer-reviewed evidence on device utilization for Black Medicare beneficiaries says the gaps live downstream of coverage-decision timing. Here is what RAPID appears to change, what it does not, and the specific Black-beneficiary group it most clearly helps.

What RAPID would change

Per coverage from the Kaiser Family Foundation CMS tracker and Fierce Healthcare, the RAPID Coverage Pathway is a replacement for the earlier Transitional Coverage for Emerging Technologies (TCET) mechanism. Devices that receive FDA Breakthrough Device Designation would be eligible for an expedited Medicare National Coverage Determination, with the pathway reducing the decision window from the roughly 12 to 18 months the standard NCD process typically runs to as short as two months. CMS published the pathway as a proposal in the Federal Register on August 11, 2026 (file code CMS-3487-NC), and its 60-day public comment period closed on October 13, 2026. The pathway takes effect only when CMS publishes a final notice.

The pathway affects manufacturer timelines and therefore the window in which a newly approved Breakthrough Device is commercially available to Medicare beneficiaries. That is a real improvement for the specific patient who would have received the device in months 13 through 18 of the standard process and will now receive it in months 3 through 6. It is not a guarantee that a given Medicare-eligible Black beneficiary will see the device prescribed, covered by their specific Medicare Advantage plan, or delivered through a nearby facility.

The utilization gaps the peer-reviewed evidence documents are downstream of timing

Three peer-reviewed studies published in the last 18 months document Black-beneficiary gaps in utilization of the device categories most likely to flow through RAPID, and each gap operates mechanisms that a coverage-speed reform does not change.

The Nosair 2025 meta-analysis cited above synthesizes 18 US AFib catheter ablation studies. The 35 percent reduced ablation odds in Black patients comes with a 22 percent reduction for Hispanic patients and a 26 percent reduction for Asian patients. The authors flag that none of the 18 studies explicitly defined disparity or the source of race and ethnicity data, which means the mechanism driving the gap is underspecified in the literature. What the evidence does say is that Black patients receive ablation less often when they are eligible for it under current coverage rules.

A 2024 JAMA Network Open analysis of continuous glucose monitor prescribing at 275 federally qualified health centers found that Black Type 2 diabetes patients had 24 percent lower odds of receiving a CGM prescription than white patients, after adjusting for relevant clinical factors (Wallia et al., PMID 39576644). The gap operates in the primary-care setting where the prescription would originate, not at the CMS coverage-determination level.

A 2025 Diabetes Spectrum paper on automated insulin delivery adoption among youth with Type 1 diabetes found that 47 percent (60 of 129) of Black youth used AID systems compared with 70 percent (341 of 483) of white youth (a statistically significant gap); Black youth who did use AID achieved a median A1C of 8 percent versus 9.6 percent in Black youth without AID (also statistically significant; Yilmaz et al., PMID 41522278). The glycemic benefit is real. The adoption gap is also real, and it closes only when Black youth actually receive the devices.

Whatever brought you to this page, community health centers see patients regardless of insurance and charge on a sliding scale by income, reducing or waiving the fee for anyone who cannot pay. Our directory of free and charitable clinics lists centers by state. A same-day telehealth visit is self-pay and is not billed to Medicaid, so if you have Medicaid the clinic route will usually cost less. If you would rather see a clinician online today:

Sesame Care

See a doctor online today.

Same-day video visits from $34

See a doctor today

Sickle cell gene therapy aligns RAPID timing with a majority-Black patient population

One device category has a specific Black-beneficiary alignment with RAPID's timing reform. Casgevy, the first FDA-approved CRISPR gene therapy for severe sickle cell disease, reached 97 percent vaso-occlusive-crisis-free status at 12 months in 30 evaluable patients in the pivotal trial (Frangoul et al., NEJM 2024, PMID 38661449). Approximately 90 percent of US sickle cell disease patients are Black, and as patients from the expanded Casgevy-eligible population age into Medicare, the coverage-determination timeline for Casgevy, Lyfgenia (both FDA-approved in December 2023), and later approvals becomes directly consequential for a majority-Black patient group.

Our earlier reporting on the ex-vivo SCD gene therapy pipeline and its access constraints is at /articles/crispr-aav-sickle-cell-access-gap/. The RAPID framework would not change the bone-marrow-harvest or myeloablative-conditioning requirements that determine which patients can complete the therapy; it would change how quickly the Medicare coverage determination for gene therapies published under Breakthrough Device Designation reaches an NCD.

Named voice on the evidence

Dr. Amisha Wallia, MD, MS, is an endocrinologist in the Division of Endocrinology at Northwestern University Feinberg School of Medicine and lead author of the 2024 JAMA Network Open CGM disparities paper. Her research documents the primary-care-setting mechanisms that produce the Black-patient CGM prescribing gap across a 275-FQHC-site sample. Her institutional page is at Northwestern Feinberg Endocrinology.

Wallia has not been interviewed for this piece; the citation above is the primary-source record under her institutional affiliation. The CGM findings are what an interview would expand into clinical and patient-coaching recommendations.

What you can do before a Breakthrough Device prescription

Three specific actions map to the evidence.

"Has this device received FDA Breakthrough Device Designation, and is Medicare covering it under the RAPID pathway?" Ask the specialist who proposes the device. The RAPID pathway is the proposed new mechanism and is not final yet; once it is, asking whether a specific device is flowing through it clarifies both the FDA-approval status and the coverage-billing category the prescription will use.

"Does the device have a National Coverage Determination, a Local Coverage Determination, or is it covered under RAPID?" Ask the provider or the device manufacturer's reimbursement support line. The answer determines billing and prior-authorization routing and affects whether out-of-pocket costs show up.

Comment on device coverage decisions as they come. The comment period on the RAPID notice itself closed on October 13, 2026; the submitted comments are public in docket CMS-2026-2674. Under the proposal, each device-specific proposed coverage decision opens its own 30-day public comment period, and beneficiaries, providers, and advocacy organizations can all comment. The coverage-pathway design decisions that affect future Breakthrough Device access are the comments' practical stakes.

For Medicare-age sickle cell disease patients specifically: ask whether the participating state Medicaid program is enrolled in the CMS Cell and Gene Therapy Access Model and whether RAPID changes the Casgevy or Lyfgenia treatment-center referral options.

What we will add

We will update this piece when CMS publishes the final RAPID notice and when the first device receives Medicare coverage through it.

Corrections

  • : Medicare device coverage: RAPID is a proposal. What we changed
  • : Figures and dates in policy explainers. What we changed

Read next

SNAP Work Rules 2026: Who Must Work and Who Is Exempt

Since July 4, 2025, SNAP's time limit covers adults ages 18 to 64 unless they have a child under 14 in their SNAP household or meet another exception. If it applies, you get 3 months of SNAP in 3 years unless you work, train or volunteer 80 hours a month. Veterans and people experiencing homelessness lost their exceptions. If you get a notice, ask for a fair hearing.

Continue reading

Medical Disclaimer

This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.

Newsletter

One email a week with essential Black health guidance, plus a featured provider.

No spam. Unsubscribe anytime.

Was this helpful?

Your feedback shapes what we cover next.

Thanks for letting us know.

If you found this useful, sign up for our newsletter to get more like this.

Thanks. What was missing?

Optional. We read every response.

Thanks.

We use this to prioritize the next round of edits.

Follow Black Health for more

More from Mark Jones

More in Policy